Nilvadipine

From Wikipedia, the free encyclopedia - View original article

Nilvadipine
Systematic (IUPAC) name
5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy cat. ?
Legal status ?
Identifiers
ATC codeC08CA10
PubChemCID 4494
DrugBankDB06712
UNII0214FUT37J YesY
KEGGD01908 YesY
ChEMBLCHEMBL517427 N
Chemical data
FormulaC19H19N3O6 
Mol. mass385.370 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Nilvadipine
Systematic (IUPAC) name
5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy cat. ?
Legal status ?
Identifiers
ATC codeC08CA10
PubChemCID 4494
DrugBankDB06712
UNII0214FUT37J YesY
KEGGD01908 YesY
ChEMBLCHEMBL517427 N
Chemical data
FormulaC19H19N3O6 
Mol. mass385.370 g/mol
 N (what is this?)  (verify)

Nilvadipine is a calcium channel blocker (CCB) used for the treatment of hypertension and chronic major cerebral artery occlusion.

Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.

Nilvadipine was tested in clinical trial as a possible treatment for Alzheimer's Disease in Ireland by the Roskamp Institute, Florida, USA and Trinity College, Ireland.[1]

Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of Nilvadipine.[2]

References